Literature DB >> 22882703

Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies.

Arne Warth1, Thomas Muley, Esther Herpel, Michael Meister, Felix J F Herth, Peter Schirmacher, Wilko Weichert, Hans Hoffmann, Philipp A Schnabel.   

Abstract

AIMS: Patient stratification according to histological subtype is important for non-small-cell lung cancer (NSCLC) therapy. For specimens with uncertain histomorphology, rational and material-saving algorithms for specific and sensitive immunotyping need to be established. METHODS AND
RESULTS: One thousand one hundred and forty-five NSCLCs were immunohistochemically investigated for the expression of cytokeratin 5/6 (CK5/6), CK7, thyroid transcription factor-1 (TTF-1), p63, napsin-A, and desmocollin-3. Overall, napsin-A and desmocollin-3 were the most specific markers (specificity of each, 99%), and CK7 and CK5/6 the most sensitive markers (sensitivity, 96% and 94%) for adenocarcinomatous and squamous differentiation, respectively. However, for NSCLC not otherwise specified (NOS) cases, TTF-1, p63, CK5/6 and CK7 were found to be the most reliable markers. On the basis of morphology alone, approximately two-thirds of all NSCLCs could be reliably diagnosed in biopsy specimens. Immunohistochemistry further reduced the NOS fraction to 10%.
CONCLUSIONS: When morphology alone is not reliable, the use of selected markers and marker panels is highly sensitive and specific, and allows reliable distinction between squamous cell carcinoma and adenocarcinoma. Considering the impact of typing for the selection of molecular testing and treatment response, one must be aware of immunomarker expression patterns in NSCLC and their diagnostic value, in order to optimize typing and thereby maximize patient benefit from chemotherapy.
© 2012 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882703     DOI: 10.1111/j.1365-2559.2012.04308.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  36 in total

Review 1.  [Lung cancer. Developments, concepts and preview of the new WHO classification].

Authors:  I Petersen; A Warth
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection.

Authors:  Maria Sromek; Maciej Glogowski; Magdalena Chechlinska; Mariusz Kulinczak; Lukasz Szafron; Klara Zakrzewska; Joanna Owczarek; Piotr Wisniewski; Robert Wlodarczyk; Lukasz Talarek; Maciej Turski; Jan Konrad Siwicki
Journal:  Cell Oncol (Dordr)       Date:  2017-06-20       Impact factor: 6.730

Review 3.  [Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing].

Authors:  A Warth; L Bubendorf; S Gütz; A Morresi-Hauf; M Hummel; K Junker; U Lehmann; I Petersen; P A Schnabel
Journal:  Pathologe       Date:  2013-07       Impact factor: 1.011

4.  A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens.

Authors:  Diana Montezuma; Rosa Azevedo; Paula Lopes; Renata Vieira; Ana Luísa Cunha; Rui Henrique
Journal:  Virchows Arch       Date:  2013-10-15       Impact factor: 4.064

5.  Pulmonary adenocarcinoma histology.

Authors:  Erik Thunnissen
Journal:  Transl Lung Cancer Res       Date:  2012-12

Review 6.  [Molecular diagnostics of non-small cell lung cancer: New markers and technologies].

Authors:  A Warth; V Endris; M Kriegsmann; A Stenzinger; R Penzel; N Pfarr; W Weichert
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

Review 7.  Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS).

Authors:  Elizabeth R Tang; Andrew M Schreiner; Bradley B Pua
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

8.  Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens.

Authors:  Mark Kriegsmann; Rita Casadonte; Jörg Kriegsmann; Hendrik Dienemann; Peter Schirmacher; Jan Hendrik Kobarg; Kristina Schwamborn; Albrecht Stenzinger; Arne Warth; Wilko Weichert
Journal:  Mol Cell Proteomics       Date:  2016-07-29       Impact factor: 5.911

Review 9.  [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].

Authors:  A Warth
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

10.  [Pathological-anatomical diagnosis according to the German lung cancer guideline 2018].

Authors:  K Junker; R Büttner; T Langer; D Ukena
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.